<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Platelet-dependent occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> at sites of deep vessel wall injury elicited by electrical stimulation of rat carotid arteries was significantly reduced by <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> (<z:chebi fb="0" ids="15627">TXA2</z:chebi>) synthetase inhibition and/or <z:chebi fb="0" ids="15627">TXA2</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxide receptor antagonism (ridogrel 1.25 mg/kg i.v.; dazoxiben 5 mg/kg i.v.; sulotroban 20 mg/kg i.v.), by inhibition of <z:chebi fb="13" ids="16761">ADP</z:chebi>-dependent platelet responses (<z:chebi fb="0" ids="9588">ticlopidine</z:chebi> 3 x 200 mg/kg orally) and by anticoagulation (<z:chebi fb="5" ids="28304">heparin</z:chebi> 250 U/kg i.v.; <z:chebi fb="8" ids="10033">warfarin</z:chebi> 1.25 mg/kg i.p.) </plain></SENT>
<SENT sid="1" pm="."><plain>This points to an involvement of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> metabolites, <z:chebi fb="13" ids="16761">ADP</z:chebi> and thrombin as modulators of the thrombotic process </plain></SENT>
<SENT sid="2" pm="."><plain>The antithrombotic effect of ridogrel (IC50 = 0.22 mg/kg i.v.) was abolished by cyclooxygenase inhibition (suprofen 5 mg/kg i.v.) but enhanced by cAMP phosphodiesterase inhibition (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> 725 6 micrograms/kg/min i.v.), demonstrating the importance of platelet inhibitory <z:chebi fb="0" ids="26347">prostanoids</z:chebi> such as <z:mp ids='MP_0002515'>PGD2</z:mp>, and prostacyclin formed after <z:chebi fb="0" ids="15627">TXA2</z:chebi> synthetase inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>High doses of ridogrel (1.25 mg/kg i.v.) producing additional <z:chebi fb="0" ids="15627">TXA2</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxide receptor antagonism were more effective than lower doses (0.16 mg/kg i.v.) providing <z:chebi fb="0" ids="15627">TXA2</z:chebi> synthetase inhibition alone </plain></SENT>
<SENT sid="4" pm="."><plain>The antithrombotic effect of ridogrel, when combined with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> or <z:chebi fb="5" ids="28304">heparin</z:chebi>, exceeded that of the single compounds, pointing to interactions between <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> metabolites, <z:chebi fb="13" ids="16761">ADP</z:chebi> and thrombin in the formation of occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> at sites of arterial injury </plain></SENT>
</text></document>